治疗iNPH:新的见解
Eric Schmidt1, Joachim K Krauss2
1Department of Neurosurgery, Toulouse University Hospital, Toulouse, France - schmidt.e@chu-toulouse.fr.
Journal of neurosurgical sciences
|March 6, 2025
概括
异常性正常压力脑症 (iNPH) 诊断应该超越症状,探索其水力动力学. 腰部输液试验提供了关于脑脊液外流抵抗的见解,有助于诊断和个性化治疗.
科学领域:
- 神经学 神经学
- 生物物理学的生物物理.
- 神经外科 神经外科
背景情况:
- 异常性正常压力脑症 (iNPH) 通常是基于症状来诊断的,可能会忽视潜在的病理生理学.
- iNPH经常与神经退行性疾病 (如阿尔茨海默氏症,帕金森症) 和血管脑病共同发生,使诊断复杂化.
- 改变的大脑水力动力学是iNPH的关键病理标志.
研究的目的:
- 倡导诊断转向研究iNPH的病理生理机制,重点关注大脑水力动力学.
- 要突出腰部输液试验的诊断实用性,以评估脑脊液 (CSF) 出流阻力.
- 建议将分流置于iNPH中作为潜在的神经调节干预措施.
主要方法:
- 对iNPH病理生理学,诊断和治疗的现有文献的审查.
- 探索大脑水力动力学和CSF外流阻力的作用.
- 分析iNPH与其他神经疾病之间的重叠.
主要成果:
- 腰部输液试验提供了对CSF外流抵抗的定量见解,作为iNPH的有价值生物标志物.
- 改变的大脑水力动力学是iNPH病理生理学的核心.
- 穿位置可能通过调节大脑流体力学来提供神经调节的好处.
结论:
- 为了准确的iNPH诊断和管理,需要基于物理的跨学科方法.
- 腰部输液试验是了解iNPH水力学的一个关键工具.
- 专注于早期检测和干预的个性化治疗策略可以改善患者的治疗结果.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
122
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
122
Pulmonary Hypertension: Classification and Pathogenesis
142
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
142
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124
COPD: Pathogenesis and Clinical Features
223
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
223


